Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

ClinicalTrials.gov ID: NCT00806026

Public ClinicalTrials.gov record NCT00806026. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double Blind, 12-Month Study Of Pregabalin In Subjects With Restless Legs Syndrome

Study identification

NCT ID
NCT00806026
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
731 participants

Conditions and interventions

Interventions

  • placebo and pregabalin Drug
  • pramipexol Drug
  • Pregabalin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2008
Primary completion
Apr 30, 2011
Completion
Apr 30, 2011
Last update posted
Jan 25, 2021

2008 – 2011

United States locations

U.S. sites
42
U.S. states
22
U.S. cities
38
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35209
Pfizer Investigational Site Jasper Alabama 35501
Pfizer Investigational Site Tuscaloosa Alabama 35406
Pfizer Investigational Site Glendale Arizona 85308
Pfizer Investigational Site Phoenix Arizona 85032
Pfizer Investigational Site Phoenix Arizona 85050
Pfizer Investigational Site Little Rock Arkansas 72205
Pfizer Investigational Site Little Rock Arkansas 72211
Pfizer Investigational Site Northridge California 91325
Pfizer Investigational Site Redondo Beach California 90277
Pfizer Investigational Site San Diego California 92103
Pfizer Investigational Site San Diego California 92121
Pfizer Investigational Site Santa Monica California 90404
Pfizer Investigational Site Torrance California 90502
Pfizer Investigational Site Aurora Colorado 80012
Pfizer Investigational Site Boca Raton Florida 33486
Pfizer Investigational Site Hallandale Florida 33009
Pfizer Investigational Site Miami Florida 33143
Pfizer Investigational Site Pembroke Pines Florida 33026
Pfizer Investigational Site South Miami Florida 33143
Pfizer Investigational Site Atlanta Georgia 30342
Pfizer Investigational Site Overland Park Kansas 66212
Pfizer Investigational Site Louisville Kentucky 40217
Pfizer Investigational Site Baton Rouge Louisiana 70808
Pfizer Investigational Site Chevy Chase Maryland 20815
Pfizer Investigational Site Newton Massachusetts 02459
Pfizer Investigational Site Southfield Michigan 48034
Pfizer Investigational Site Minneapolis Minnesota 55415
Pfizer Investigational Site Princeton New Jersey 08540
Pfizer Investigational Site New York New York 10019
Pfizer Investigational Site Salisbury North Carolina 28144-0000
Pfizer Investigational Site Salisbury North Carolina 28144
Pfizer Investigational Site Winston-Salem North Carolina 27103
Pfizer Investigational Site Cincinnati Ohio 45219
Pfizer Investigational Site Columbus Ohio 43210
Pfizer Investigational Site Oklahoma City Oklahoma 73112
Pfizer Investigational Site Lafayette Hill Pennsylvania 19444
Pfizer Investigational Site Austin Texas 78731
Pfizer Investigational Site Dallas Texas 75231
Pfizer Investigational Site Houston Texas 77063
Pfizer Investigational Site Plano Texas 75093
Pfizer Investigational Site Walla Walla Washington 99362

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 68 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00806026, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 25, 2021 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00806026 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →